Celltrion Pharm, Inc. (068760.KQ)
KRW 61300.0
(-3.01%)
KRW 61300.0
(-3.01%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 641.64 Billion KRW | 6.99% |
| 2022 | 599.72 Billion KRW | -5.98% |
| 2021 | 637.88 Billion KRW | 16.39% |
| 2020 | 548.07 Billion KRW | 16.37% |
| 2019 | 470.98 Billion KRW | 4.1% |
| 2018 | 452.44 Billion KRW | -3.79% |
| 2017 | 470.26 Billion KRW | 6.38% |
| 2016 | 442.08 Billion KRW | -5.29% |
| 2015 | 466.77 Billion KRW | 113424.31% |
| 2014 | 411.16 Million KRW | 13.78% |
| 2013 | 361.35 Million KRW | 9.16% |
| 2012 | 331.04 Million KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 639.78 Billion KRW | 0.6% |
| 2024 Q1 | 635.99 Billion KRW | -0.88% |
| 2023 Q4 | 641.64 Billion KRW | -0.02% |
| 2023 Q1 | 616.87 Billion KRW | 2.86% |
| 2023 Q2 | 621.74 Billion KRW | 0.79% |
| 2023 FY | 641.64 Billion KRW | 6.99% |
| 2023 Q3 | 641.77 Billion KRW | 3.22% |
| 2022 FY | 599.72 Billion KRW | -5.98% |
| 2022 Q3 | 595.29 Billion KRW | 0.11% |
| 2022 Q2 | 594.65 Billion KRW | -2.61% |
| 2022 Q1 | 610.58 Billion KRW | -4.28% |
| 2022 Q4 | 599.72 Billion KRW | 0.74% |
| 2021 Q3 | 597.86 Billion KRW | 6.25% |
| 2021 Q1 | 572.89 Billion KRW | 104429.33% |
| 2021 FY | 637.88 Billion KRW | 16.39% |
| 2021 Q4 | 637.88 Billion KRW | 6.69% |
| 2021 Q2 | 562.68 Billion KRW | -1.78% |
| 2020 FY | 548.07 Billion KRW | 16.37% |
| 2020 Q1 | 486.94 Million KRW | 3.39% |
| 2020 Q2 | 501.37 Million KRW | 2.96% |
| 2020 Q3 | 527.83 Million KRW | 5.28% |
| 2020 Q4 | 548.07 Million KRW | 3.83% |
| 2019 Q3 | 455.47 Million KRW | -1.13% |
| 2019 Q2 | 460.66 Million KRW | 3.31% |
| 2019 FY | 470.98 Billion KRW | 4.1% |
| 2019 Q1 | 445.91 Million KRW | -1.44% |
| 2019 Q4 | 470.98 Million KRW | 3.4% |
| 2018 Q2 | 495.29 Million KRW | 0.69% |
| 2018 Q1 | 491.89 Million KRW | 4.6% |
| 2018 FY | 452.44 Billion KRW | -3.79% |
| 2018 Q4 | 452.44 Million KRW | 0.31% |
| 2018 Q3 | 451.04 Million KRW | -8.94% |
| 2017 FY | 470.26 Billion KRW | 6.38% |
| 2017 Q1 | 500.8 Million KRW | 13.28% |
| 2017 Q3 | 513.34 Million KRW | 1.11% |
| 2017 Q2 | 507.7 Million KRW | 1.38% |
| 2017 Q4 | 470.26 Million KRW | -8.39% |
| 2016 FY | 442.08 Billion KRW | -5.29% |
| 2016 Q2 | 477.41 Million KRW | 1.57% |
| 2016 Q1 | 470.03 Million KRW | 11.16% |
| 2016 Q3 | 484.42 Million KRW | 1.47% |
| 2016 Q4 | 442.08 Million KRW | -8.74% |
| 2015 Q4 | 422.85 Million KRW | -9.61% |
| 2015 FY | 466.77 Billion KRW | 113424.31% |
| 2015 Q1 | 438.02 Million KRW | 6.53% |
| 2015 Q3 | 467.78 Million KRW | 4.78% |
| 2015 Q2 | 446.44 Million KRW | 1.92% |
| 2014 Q1 | 363.28 Million KRW | 0.53% |
| 2014 Q2 | 377.06 Million KRW | 3.79% |
| 2014 Q3 | 383.64 Million KRW | 1.74% |
| 2014 Q4 | 411.16 Million KRW | 7.17% |
| 2014 FY | 411.16 Million KRW | 13.78% |
| 2013 Q3 | 344.56 Million KRW | 1.13% |
| 2013 Q1 | 328.75 Million KRW | -0.69% |
| 2013 Q2 | 340.71 Million KRW | 3.64% |
| 2013 Q4 | 361.35 Million KRW | 4.87% |
| 2013 FY | 361.35 Million KRW | 9.16% |
| 2012 Q4 | 331.04 Million KRW | 0.0% |
| 2012 FY | 331.04 Million KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 141.35 Billion KRW | -353.934% |
| CMG Pharmaceutical Co., Ltd. | 186.85 Billion KRW | -243.397% |
| Huons Global Co., Ltd. | 1317.96 Billion KRW | 51.316% |
| DongKook Pharmaceutical Co., Ltd. | 839.53 Billion KRW | 23.572% |
| Enzychem Lifesciences Corporation | 211.54 Billion KRW | -203.312% |
| Humedix Co., Ltd. | 219.97 Billion KRW | -191.686% |
| Boditech Med Inc. | 227.9 Billion KRW | -181.544% |
| EuBiologics Co., Ltd. | 172.64 Billion KRW | -271.662% |
| FutureChem Co.,Ltd | 72.83 Billion KRW | -780.977% |
| Huons Co., Ltd. | 537.28 Billion KRW | -19.423% |
| BNC Korea Co., Ltd. | 236.15 Billion KRW | -171.707% |
| AptaBio Therapeutics Inc. | 92.51 Billion KRW | -593.525% |